

REGULATION OF ESTROGEN PRODUCTION IN UTERINE FIBROIDS


Serdar Bulun, MD

Professor and Friends of Prentice

Distinguished Physician



**Chief, Division of Reproductive Biology
Research, Dept of Ob/Gyn**

Northwestern University, Chicago, IL




StAR

P450scc





MITOCHONDRION

3 β -HSD-II





nmol/L

P450c17




3 β -HSD-II

P450c17




P450c17



3 β -HSD-II


P450c17





17 β -HSD-1



P450arom




P450arom



17 β -HSD-1


pmol/L




Recent Breast Cancer Trials: Tamoxifen vs Aromatase Inhibitors

		<u>No of Participants</u>	<u>Response to Tx</u>		<u>Time to Prog</u>	
			AromIn	TAM	AromIn	TAM
1st line therapy in advanced disease	2001 Letrozole vs TAM	907	49%*	38%	9.5 mo*	6 mo
	2000 Anastrozole vs TAM	353	59%*	46%	11.1 mo*	5.6 mo
	2001 Anastrozole vs TAM	668	56%	55%	8.2 mo	8.3 mo
	2000 Anastrozole vs TAM	121	34%*	27%	10.6 mo*	5.3 mo
	2000 Exemestane vs TAM	107	52%	41%	8.9 mo	5.2 mo
Neoadj tx	2001 Letrozole vs TAM	250	60%*	41%		
Adj tx	<u>ATAC</u>					
	2002 Anastrozole vs TAM	9366		<u>No of Recurrences</u> 223*	264	
Contralat ca prevention	2002 Anastrozole vs TAM	9366		<u>No of Contralat Breast Ca</u> 14*	33	

ESTROGEN PRODUCTION IN HUMAN TISSUES





CYP19 (aromatase) GENE









P450arom mRNA


TISSUE P450arom TRANSCRIPTS DETECTED







Noble et al, JCEM, 1996
Noble et al, JCEM, 1997
Zeitoun et al, Mol Endo, 1999








Tamura et al, JBC, 2002
Tamura et al, JCEM, 2002
Tamura et al, MCE, 2003




Tamura et al, JCEM, 2002
Tamura et al, Fertil Steril, 2004

ENDOMETRIOSIS



NORMAL ENDOMETRIUM



Zeitoun, et al, Mol Endo, 1999; Yang, et al, JCEM 2002; Gurates, et al, JCEM 2002

PGE₂

cAMP

ENDOMETRIOSIS

ENDOMETRIOSIS

Co-activator (1)

Co-activator (1)

Co-Act (2)

Co-Act (2)

SF-1

Enh

C/EBP

C/EBP

Enh

SF-1

NRHS

CRS

CRS

NRHS

StAR

aromatase

ENDOMETRIUM

ENDOMETRIUM

Co-Repressor (1)

Co-Repressor (1)

COUP-TF

WT-1

?LRH-1

Inh

C/EBP

C/EBP

Inh

COUP-TF

WT-1

?LRH-1

NRHS

CRS


CRS


NRHS

StAR


aromatase

Takayama et al, Fertil Steril, 1998
Ailawadi et al, Fertil Steril, 2004
Soysal et al, Human Reproduction, 2004
Amsterdam et al, Fertil Steril, in press






DISEASE-FREE BREAST ADIPOSE




 mature adipocyte

BREAST CANCER


malignant epithelial cell




 fibroblasts, endothelial cells



Zhou et al, Cancer Res, 2001






DISTRIBUTION OF AROMATASE PROMOTERS IN BREAST CANCER SAMPLES (n=5):

Number of 5'-RACE Clones sequenced	I.7	PII	I.3	I.4	Total
Breast Cancer 1	4	3	4	3	14
Normal Breast				10	10


5'-RACE/ Colony hybridization	Percentage of I.7-specific clones
Breast Cancer 2	39%
Breast Cancer 3	42%
Breast Cancer 4	42%
Breast Cancer 5	54%

TOTAL AROMATASE mRNA LEVELS:



aromatase mRNA species in normal breast

+



aromatase mRNA species in breast cancer

++++

LEIOMYOMAS AND ESTROGEN-PROGESTERONE

- **Leiomyoma growth is dependent on ovarian steroids.**
- **Conditions associated with increased estrogen and progesterone (e.g., pregnancy and HRT) result in growth of leiomyomata.**
- **On the other hand, conditions in which ovarian steroid concentrations are diminished (menopause and GnRHa therapy) result in a decrease in size of the leiomyomata.**


LEIOMYOMAS AND ESTROGEN-PROGESTERONE

- **The ovary represents a very important source of estrogen and progesterone necessary for leiomyoma growth.**
- **Leiomyoma tissues are themselves a source of estrogen.**
- **The tissue concentrations of estrogens are elevated in leiomyoma nodules compared with levels in the surrounding myometrium.**

HISTORY - AROMATASE

- Leiomyoma tissue possesses high aromatase enzyme activity, whereas normal myometrium displays no activity (Folkerd et al and Yamamoto et al, 1984).
- We demonstrated that LSMCs in culture are capable of aromatizing androstenedione to estrogen (Bulun et al, 1994).
- Levels of aromatase mRNA are 1.5-25 times higher in leiomyomata than in surrounding myometrium (Bulun et al, 1994).
- Immunoreactive aromatase is strongly expressed in smooth muscle cells of leiomyoma and in smooth muscle cells of the tunica intima of arterioles, but not in other cell components such as blood cells infiltrating leiomyoma tissues (Shozu et al, 2000).


Primary Leiomyoma Smooth Muscle Cells




Shozu et al, JCEM, 2000


Uterine leiomyoma in a perimenopausal Japanese woman shrank significantly (>50%) after treatment with the aromatase inhibitor fadrozole.

REGULATION OF AROMATASE ACTIVITY AND EXPRESSION






Identification of Promoter Use Specific for Leiomyoma Tissue from Japanese Women



- Real-Time PCR: 16 of 20 nodules contained only I.4-specific mRNA.
- The remaining 4 leiomyoma nodules were positive for both PII and I.4-specific mRNA.
- 5'-RACE: 5 out of 6 leiomyomata from Japanese patients contained I.4, whereas only 2/6 contained PII-specific mRNA.



Placenta:

I.1	Arom Coding Region
-----	--------------------

Brain:

I.f	Arom Coding Region
-----	--------------------

Adipose Tissue:

I.4	Arom Coding Region
-----	--------------------

Breast cancer:

I.3	Arom Coding Region
-----	--------------------


Ovary/endometriosis:

PII	Arom Coding Region
-----	--------------------

PII	Arom Coding Region
-----	--------------------

I.7	Arom Coding Region
-----	--------------------


5'-RACE




PROMOTER-SPECIFIC AROMATASE mRNA SPECIES BY 5'-RACE


Patient	Tissue	Race	Age	Mens cycle	Pr I.3	Pr II	Pr I.6	Pr 2.a	Pr I.4
1	LM	AA	39	Follicular	(+)			(+)	
	LM	AA	39	Follicular		(+)			
2	LM	White	42	Follicular	(+)				
	MYO	White	42	Follicular	(+)				
3	LM	Hispanic	65	Postmen	(+)				
4	LM	AA	41	Luteal	(+)			(+)	
5	LM	White	42	Luteal					(+)
6	LM	Hispanic	42	Luteal	(+)				
7	LM	AA	40	Luteal		(+)	(+)		
8	LM	White	54	Postmen	(+)		(+)		
9	LM	AA	45	Follicular	(+)				
10	LM	Hispanic	54	Postmen			(+)	(+)	
11	LM	White	38	Follicular					(+)
12	LM	AA	37	Follicular	(+)				
13	LM	AA	39	Follicular	(+)	(+)	(+)		
14	LM	AA	36	Luteal	(+)				
15	LM	AA	45	Follicular	(+)	(+)			
16	LM	AA	42	Luteal				(+)	
17	LM	White	42	Follicular	(+)				

PROMOTER-SPECIFIC AROMATASE mRNA SPECIES IN HUMAN UTERINE LEIOMYOMATA AND MYOMETRIAL TISSUES BY 5'-RACE (N=17)



REAL TIME PCR (N=28)







-576 gtcctaggg atactgttta atctggccca tggtaacaaga gattttagat cttcattgaa
 -516 gtcactagag atggcctgag tgagcacttt gaattcatta gacaactgat ggaaggctct
 -456 gagaagacct caacgatgcc caagaaatgt gttcttactg tagaaacta ctattttgat
 -396 caaaaaagtc attttggtca aaaaggggag ttgggagatt gcctttttgt tttgaaattg
 -336 atttggcttc aagggaagaa gattgcctaa acaaaacctg ctgatgaagt cacaaaatga
 -276 ctccacctct ggaatgagct ttattttctt ataattggc aagaaattg gctttcaatt
 -216 gggaatgcac gtcactctac ccactcaagg gcaagatgat aaggttctat cagaccaagc
 -156 gtctaaagga acctgagact ctaccaaggt cagaaatgct gcaattcaag ccaaaagatc
 -96 tttcttgggc ttcttggtt tgacttgtaa ccataaatta gtcttgctta aatgtctgat
 -36 cacattataa aacagtaagt gaatctgtac tgtacagcac

PII TATA box

AROMATASE EXPRESSION AND TRANSCRIPTION FACTORS

	Endometrium	Endometriosis
Aromatase	-	++++
SF-1	-	++++
LRH-1	++	++

	Myometrium	Leiomyoma
Aromatase	-	++++
SF-1	+	+
LRH-1	+	+



BULUN LAB

Zhihong Lin
Santanu Deb
Masashi Demura
Hiroki Utsunomiya
Gonca Imir
Masashi Demura
Sanober Amin
Bertan Yilmaz
Regina Martin
Dong Chen
Youhon Cheng
Ping Yin

David Langoi
Makio Shozu
Bilgin Gurates
Siby Sebastian
Mitsutoshi Tamura
Khaled Zeitoun
Kazuto Takayama
Luis Noble

Roger Schultz
William Rainey
Hossain Saborian
Hironobu Sasano
Takashi Suzuki
Evan Simpson
Asgi Fazleabas
Michael Putman
Alan Johns
David Redwine